Last reviewed · How we verify

NCT03264781

The Effect of Cyclofem® for the Treatment of Irregular Uterine Bleeding in Implant Contraceptive Users; a Randomized Controlled Trial

Status unknown Phase 1/Phase 2 Last updated 29 August 2017
What this trial tests

Phase 1/Phase 2 trial testing Cyclofem in Uterine Bleeding in 44 participants. Status unknown.

Timeline
1 August 2016
Primary endpoint
1 December 2017
1 December 2017

Quick facts

Lead sponsorChulalongkorn University
PhasePhase 1/Phase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment44
Start date1 August 2016
Primary completion1 December 2017
Estimated completion1 December 2017
Sites1 location across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

Chulalongkorn University

Who can join

18 and older, female only, with Uterine Bleeding. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to determine that once-a-month injectable contraceptive( Cyclofem® ) has the effect on treatment of irregular uterine bleeding in implant contraceptive users or not.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Uterine Bleeding

Currently open trials in the same condition.

Other Chulalongkorn University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03264781.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing